The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Hereditary Angioedema-Global Market Insights and Sales Trends 2024
Synopsis
Hereditary angioedema is a rare disease and is mostly mistaken for common allergic reactions and abdominal pain. This mainly on account of the lack of knowledge among both physicians and patients about the condition. About 40% of the affected patients are diagnosed correctly with hereditary angioedema in the US and Europe. With progress in diagnostic field and different initiatives undertaken by patient bodies and industry players to spread awareness, the market for hereditary angioedema is projected to grow.
The global Hereditary Angioedema market size is expected to reach US$ 2724.1 million by 2029, growing at a CAGR of 7.3% from 2023 to 2029. The market is mainly driven by the significant applications of Hereditary Angioedema in various end use industries. The expanding demands from the Retail Pharmacies, Hospital Pharmacies and Online Pharmacies,, are propelling Hereditary Angioedema market. C1 Esterase Inhibitor, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Kallikrein Inhibitor segment is estimated at % CAGR for the next seven-year period.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Distribution Channel. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hereditary Angioedema, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hereditary Angioedema market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hereditary Angioedema market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hereditary Angioedema sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hereditary Angioedema covered in this report include Pharming Group NV, Takeda, CSL Limited, iBio Inc., BioCryst Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc., etc.
The global Hereditary Angioedema market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pharming Group NV
Takeda
CSL Limited
iBio Inc.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Global Hereditary Angioedema market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hereditary Angioedema market, Segment by Type:
C1 Esterase Inhibitor
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
Global Hereditary Angioedema market, by Distribution Channel
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Hereditary Angioedema manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Hereditary Angioedema in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Distribution Channel, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Hereditary angioedema is a rare disease and is mostly mistaken for common allergic reactions and abdominal pain. This mainly on account of the lack of knowledge among both physicians and patients about the condition. About 40% of the affected patients are diagnosed correctly with hereditary angioedema in the US and Europe. With progress in diagnostic field and different initiatives undertaken by patient bodies and industry players to spread awareness, the market for hereditary angioedema is projected to grow.
The global Hereditary Angioedema market size is expected to reach US$ 2724.1 million by 2029, growing at a CAGR of 7.3% from 2023 to 2029. The market is mainly driven by the significant applications of Hereditary Angioedema in various end use industries. The expanding demands from the Retail Pharmacies, Hospital Pharmacies and Online Pharmacies,, are propelling Hereditary Angioedema market. C1 Esterase Inhibitor, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Kallikrein Inhibitor segment is estimated at % CAGR for the next seven-year period.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Distribution Channel. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hereditary Angioedema, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hereditary Angioedema market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hereditary Angioedema market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hereditary Angioedema sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hereditary Angioedema covered in this report include Pharming Group NV, Takeda, CSL Limited, iBio Inc., BioCryst Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc., etc.
The global Hereditary Angioedema market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pharming Group NV
Takeda
CSL Limited
iBio Inc.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Global Hereditary Angioedema market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hereditary Angioedema market, Segment by Type:
C1 Esterase Inhibitor
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
Global Hereditary Angioedema market, by Distribution Channel
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Hereditary Angioedema manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Hereditary Angioedema in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Distribution Channel, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Hereditary Angioedema Market Overview
1.1 Hereditary Angioedema Product Overview
1.2 Hereditary Angioedema Market Segment by Type
1.2.1 C1 Esterase Inhibitor
1.2.2 Kallikrein Inhibitor
1.2.3 Selective Bradykinin B2 Receptor Antagonist
1.3 Global Hereditary Angioedema Market Size by Type
1.3.1 Global Hereditary Angioedema Market Size Overview by Type (2018-2029)
1.3.2 Global Hereditary Angioedema Historic Market Size Review by Type (2018-2023)
1.3.3 Global Hereditary Angioedema Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Hereditary Angioedema Sales Breakdown by Type (2018-2023)
1.4.2 Europe Hereditary Angioedema Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Hereditary Angioedema Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Hereditary Angioedema Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Hereditary Angioedema Sales Breakdown by Type (2018-2023)
2 Global Hereditary Angioedema Market Competition by Company
2.1 Global Top Players by Hereditary Angioedema Sales (2018-2023)
2.2 Global Top Players by Hereditary Angioedema Revenue (2018-2023)
2.3 Global Top Players by Hereditary Angioedema Price (2018-2023)
2.4 Global Top Manufacturers Hereditary Angioedema Manufacturing Base Distribution, Sales Area, Product Type
2.5 Hereditary Angioedema Market Competitive Situation and Trends
2.5.1 Hereditary Angioedema Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Hereditary Angioedema Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hereditary Angioedema as of 2022)
2.7 Date of Key Manufacturers Enter into Hereditary Angioedema Market
2.8 Key Manufacturers Hereditary Angioedema Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Hereditary Angioedema Status and Outlook by Region
3.1 Global Hereditary Angioedema Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Hereditary Angioedema Historic Market Size by Region
3.2.1 Global Hereditary Angioedema Sales in Volume by Region (2018-2023)
3.2.2 Global Hereditary Angioedema Sales in Value by Region (2018-2023)
3.2.3 Global Hereditary Angioedema Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Hereditary Angioedema Forecasted Market Size by Region
3.3.1 Global Hereditary Angioedema Sales in Volume by Region (2024-2029)
3.3.2 Global Hereditary Angioedema Sales in Value by Region (2024-2029)
3.3.3 Global Hereditary Angioedema Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Hereditary Angioedema by Distribution Channel
4.1 Hereditary Angioedema Market Segment by Distribution Channel
4.1.1 Retail Pharmacies
4.1.2 Hospital Pharmacies
4.1.3 Online Pharmacies
4.2 Global Hereditary Angioedema Market Size by Distribution Channel
4.2.1 Global Hereditary Angioedema Market Size Overview by Distribution Channel (2018-2029)
4.2.2 Global Hereditary Angioedema Historic Market Size Review by Distribution Channel (2018-2023)
4.2.3 Global Hereditary Angioedema Forecasted Market Size by Distribution Channel (2024-2029)
4.3 Key Regions Market Size Segment by Distribution Channel
4.3.1 North America Hereditary Angioedema Sales Breakdown by Distribution Channel (2018-2023)
4.3.2 Europe Hereditary Angioedema Sales Breakdown by Distribution Channel (2018-2023)
4.3.3 Asia-Pacific Hereditary Angioedema Sales Breakdown by Distribution Channel (2018-2023)
4.3.4 Latin America Hereditary Angioedema Sales Breakdown by Distribution Channel (2018-2023)
4.3.5 Middle East and Africa Hereditary Angioedema Sales Breakdown by Distribution Channel (2018-2023)
5 North America Hereditary Angioedema by Country
5.1 North America Hereditary Angioedema Historic Market Size by Country
5.1.1 North America Hereditary Angioedema Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Hereditary Angioedema Sales in Volume by Country (2018-2023)
5.1.3 North America Hereditary Angioedema Sales in Value by Country (2018-2023)
5.2 North America Hereditary Angioedema Forecasted Market Size by Country
5.2.1 North America Hereditary Angioedema Sales in Volume by Country (2024-2029)
5.2.2 North America Hereditary Angioedema Sales in Value by Country (2024-2029)
6 Europe Hereditary Angioedema by Country
6.1 Europe Hereditary Angioedema Historic Market Size by Country
6.1.1 Europe Hereditary Angioedema Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Hereditary Angioedema Sales in Volume by Country (2018-2023)
6.1.3 Europe Hereditary Angioedema Sales in Value by Country (2018-2023)
6.2 Europe Hereditary Angioedema Forecasted Market Size by Country
6.2.1 Europe Hereditary Angioedema Sales in Volume by Country (2024-2029)
6.2.2 Europe Hereditary Angioedema Sales in Value by Country (2024-2029)
7 Asia-Pacific Hereditary Angioedema by Region
7.1 Asia-Pacific Hereditary Angioedema Historic Market Size by Region
7.1.1 Asia-Pacific Hereditary Angioedema Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Hereditary Angioedema Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Hereditary Angioedema Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Hereditary Angioedema Forecasted Market Size by Region
7.2.1 Asia-Pacific Hereditary Angioedema Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Hereditary Angioedema Sales in Value by Region (2024-2029)
8 Latin America Hereditary Angioedema by Country
8.1 Latin America Hereditary Angioedema Historic Market Size by Country
8.1.1 Latin America Hereditary Angioedema Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Hereditary Angioedema Sales in Volume by Country (2018-2023)
8.1.3 Latin America Hereditary Angioedema Sales in Value by Country (2018-2023)
8.2 Latin America Hereditary Angioedema Forecasted Market Size by Country
8.2.1 Latin America Hereditary Angioedema Sales in Volume by Country (2024-2029)
8.2.2 Latin America Hereditary Angioedema Sales in Value by Country (2024-2029)
9 Middle East and Africa Hereditary Angioedema by Country
9.1 Middle East and Africa Hereditary Angioedema Historic Market Size by Country
9.1.1 Middle East and Africa Hereditary Angioedema Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Hereditary Angioedema Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Hereditary Angioedema Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Hereditary Angioedema Forecasted Market Size by Country
9.2.1 Middle East and Africa Hereditary Angioedema Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Hereditary Angioedema Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Pharming Group NV
10.1.1 Pharming Group NV Company Information
10.1.2 Pharming Group NV Introduction and Business Overview
10.1.3 Pharming Group NV Hereditary Angioedema Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Pharming Group NV Hereditary Angioedema Products Offered
10.1.5 Pharming Group NV Recent Development
10.2 Takeda
10.2.1 Takeda Company Information
10.2.2 Takeda Introduction and Business Overview
10.2.3 Takeda Hereditary Angioedema Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Takeda Hereditary Angioedema Products Offered
10.2.5 Takeda Recent Development
10.3 CSL Limited
10.3.1 CSL Limited Company Information
10.3.2 CSL Limited Introduction and Business Overview
10.3.3 CSL Limited Hereditary Angioedema Sales, Revenue and Gross Margin (2018-2023)
10.3.4 CSL Limited Hereditary Angioedema Products Offered
10.3.5 CSL Limited Recent Development
10.4 iBio Inc.
10.4.1 iBio Inc. Company Information
10.4.2 iBio Inc. Introduction and Business Overview
10.4.3 iBio Inc. Hereditary Angioedema Sales, Revenue and Gross Margin (2018-2023)
10.4.4 iBio Inc. Hereditary Angioedema Products Offered
10.4.5 iBio Inc. Recent Development
10.5 BioCryst Pharmaceuticals, Inc.
10.5.1 BioCryst Pharmaceuticals, Inc. Company Information
10.5.2 BioCryst Pharmaceuticals, Inc. Introduction and Business Overview
10.5.3 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Sales, Revenue and Gross Margin (2018-2023)
10.5.4 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Products Offered
10.5.5 BioCryst Pharmaceuticals, Inc. Recent Development
10.6 Ionis Pharmaceuticals, Inc.
10.6.1 Ionis Pharmaceuticals, Inc. Company Information
10.6.2 Ionis Pharmaceuticals, Inc. Introduction and Business Overview
10.6.3 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Products Offered
10.6.5 Ionis Pharmaceuticals, Inc. Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Hereditary Angioedema Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Hereditary Angioedema Industrial Chain Analysis
11.4 Hereditary Angioedema Market Dynamics
11.4.1 Hereditary Angioedema Industry Trends
11.4.2 Hereditary Angioedema Market Drivers
11.4.3 Hereditary Angioedema Market Challenges
11.4.4 Hereditary Angioedema Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Hereditary Angioedema Distributors
12.3 Hereditary Angioedema Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
